Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) have been given an average rating of “Buy” by the five research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company.

Several brokerages have recently commented on CURLF. Zacks Research upgraded shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. ATB Capital raised shares of Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd. Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. Atb Cap Markets raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Finally, Canaccord Genuity Group raised Curaleaf to a “strong-buy” rating in a research note on Thursday, October 9th.

Curaleaf Stock Down 3.1%

OTCMKTS:CURLF opened at $2.47 on Wednesday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -7.72 and a beta of 0.73. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.71 and a current ratio of 1.47. The stock’s fifty day moving average price is $2.68 and its two-hundred day moving average price is $2.57. Curaleaf has a 52-week low of $0.68 and a 52-week high of $5.05.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. On average, analysts anticipate that Curaleaf will post -0.25 EPS for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.